STOCK TITAN
  1. Home
  2. News
  3. ECOR

electroCore to Participate at Annual Aegis Virtual Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

ROCKAWAY, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR) a commercial-stage bioelectronic medicine and wellness company, today announced that electroCore’s Chief Executive Officer, Dan Goldberger, will present at the Annual Aegis Virtual Conference being held May 2-4, 2023.

Aegis Capital Conference:
Date: Tuesday, May 2, 2023
Time: 4:00 PM ET
Event: Presentation here

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.

For more information, visit www.electrocore.com.

Investors:
Rich Cockrell
CG Capital
404-736-3838
ecor@cg.capital


Stock ECOR logo
electroCore, Inc.

NASDAQ:ECOR

ECOR Rankings

#4847 Ranked by Market Cap
#411 Ranked by Stock Gains
N/A Ranked by Dividends

ECOR Latest News

May 3, 2024
electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
May 1, 2024
electroCore to Announce First Quarter March 31, 2024 Financial Results on Wednesday, May 8, 2024
Apr 30, 2024
Truvaga™ Plus Demonstrates Health Benefits in Latest Consumer Study, Paving the Way for Market Expansion
Apr 8, 2024
electroCore Announces the Launch of Truvaga Plus® for General Wellness
Apr 2, 2024
electroCore Expands Intellectual Property Portfolio

ECOR Stock Data

42.02M
4.17M
18.51%
16.59%
0.17%
Electromedical and Electrotherapeutic Apparatus Manufacturing
Manufacturing
Link
United States of America
ROCKAWAY

About ECOR

electrocore is, a us based electroceutical healthcare company, which is developing a range of non-invasive vagus nerve stimulation (nvns) patient administered therapies for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and other fields. initial focus is on primary headache (migraine and cluster headache), with trials continuing in epilepsy, gastric motility disorders, depression and anxiety. electrocore, which was founded in 2005, has more than 30 employees and full time consultants with offices in the us (head office), germany (german and european head office), uk, italy, australia, and canada.